• Publications
  • Influence

Claim Your Author Page
Ensure your research is discoverable on Semantic Scholar. Claiming your author page allows you to personalize the information displayed and manage your publications. Semantic Scholar automatically creates author pages based on data aggregated from public sources and our publisher partners.
  • Ihor Bekersky, Robert Michael George Fielding, Dawna E Dressler, Jean W. Lee, Donald N. Buell, Thomas Walsh
  • Medicine, Chemistry
  • Antimicrobial Agents and Chemotherapy
  • 2002 (First Publication: 1 March 2002)
  • ABSTRACT The pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) (liposomal AMB) and the conventional formulation, AMB deoxycholate (AMB-DOC), were compared in aContinue Reading
  • Ihor Bekersky, Robert Michael George Fielding, Dawna E Dressler, Jean W. Lee, Donald N. Buell, Thomas Walsh
  • Medicine, Chemistry
  • Antimicrobial Agents and Chemotherapy
  • 2002 (First Publication: 1 March 2002)
  • ABSTRACT Unilamellar liposomal amphotericin B (AmBisome) (liposomal AMB) reduces the toxicity of this antifungal drug. The unique composition of liposomal AMB stabilizes the liposomes, producingContinue Reading
  • T J Walsh, Jessica L. Goodman, +5 authors Elias J. Anaissie
  • Medicine
  • Antimicrobial Agents and Chemotherapy
  • 2001 (First Publication: 1 December 2001)
  • ABSTRACT We conducted a phase I-II study of the safety, tolerance, and plasma pharmacokinetics of liposomal amphotericin B (L-AMB; AmBisome) in order to determine its maximally tolerated dosage (MTD)Continue Reading
  • T J Walsh, Vijay Yeldandi, +12 authors W Wilson
  • Medicine
  • Antimicrobial Agents and Chemotherapy
  • 1998 (First Publication: 1 September 1998)
  • ABSTRACT The safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) administered for empirical antifungal therapy were evaluated for 36Continue Reading
  • Mary F. Hebert, Helen E Smith, +6 authors Ihor Bekersky
  • Medicine
  • Journal of clinical pharmacology
  • 2005 (First Publication: 1 October 2005)
  • Micafungin is an antifungal agent metabolized by arylsulfatase with secondary metabolism by catechol-O-methyltransferase. The objectives of this study were to estimate the pharmacokinetic parametersContinue Reading
  • Vidmantas Petraitis, Ruta Petraitiene, +7 authors Thomas Walsh
  • Medicine, Biology
  • Antimicrobial Agents and Chemotherapy
  • 2002 (First Publication: 1 June 2002)
  • ABSTRACT Micafungin (FK463) is an echinocandin that demonstrates potent in vitro antifungal activities against Candida and Aspergillus species. However, little is known about its comparativeContinue Reading